Back to results
US 2026/0297201 A1Published application
Egfr and c-met binding agent variants and methods of use
AssigneeJanssen Biotech, Inc.
InventorsNuriye Berkay, Ping Hu, Qingrong Yan, Harsh Sharma
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to EGFR/c-Met binding agent variants, compositions comprising EGFR/c-Met binding agent variants, and uses thereof.
Claims10
A composition comprising:
- a variant EGFR/c-Met binding agent comprising a first polypeptide comprising SEQ ID NO:
- 17, a second polypeptide comprising SEQ ID NO:
- 18, a third polypeptide comprising SEQ ID NO:
- 19, and a fourth polypeptide comprising SEQ ID NO:
- 20, wherein Asp99 of SEQ ID NO:
- 17 is isomerized,
- wherein the residue numbering starts from N-terminus of SEQ ID NO:
- 17, and a hyaluronidase.
5 more elements
Dependencies are inferred from the claim text.